Press Room


    Press Release - July 10, 2006

    Charles Allard Appointed to Board of Directors

    Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Mr. Charles Allard, LLB of Edmonton, Alberta, has been appointed to the Board of Directors to assist Pheromone in its diabetes product development. Mr. Allard brings with him a history of successful business ventures in many fields including broadcasting, banking and real estate development.

    Mr. Allard is presently a Director of Canadian Western Bank, Cathton Holding Ltd. and Allarco Entertainment Inc., and is President of Rosedale Meadow Developments Inc. He previously held board positions with WIC Premium Television Ltd., Canadian Satellite Communications Corp., ExpressVu Inc., Western International Communications Inc. The Family Channel, Teletoon, Northwest Trust Company and Allarco Developments. He has also recently been appointed a Director of the Alberta Diabetes Institute Advisory Board. He is active in several charitable organizations and serves as a Director of Young Life of Canada.

    Mr. Allard completed his law degree at the University of British Columbia after graduating from Simon Fraser University's Bachelor of Science program. He was admitted to the Alberta Bar in 1973 and has practiced law continuously since then.

    "We are delighted to have Mr. Allard join with us in moving this company towards a breakthrough in diabetes treatment," said Pheromone's Chairman Dr. William Cochrane. "He has shown his commitment to improving the lives of people with diabetes through his investments and charitable support of diabetes treatment and research."

    About the Research Project Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Using rigorous and widely accepted scientific experimentation methods, the Company intends to develop a procedure for transplanting into humans a device containing pig islet cells and pig Sertoli cells. The islet cells produce insulin almost identical to that found in humans and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The goal of the project is to ultimately receive approval for the procedure from the United States Food and Drug Administration, and from other national regulatory bodies throughout the developed world. The research is based on several proof- of-concept experiments completed by Dr. David White, Pheromone's principal researcher, and others.

    Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.


    "Dev Randhawa"

    Dev Randhawa, CEO

    For further information contact:

    Mr. Phil Morehouse Pheromone Sciences Corp.

    TEL: (250) 868-8177 FAX: (250) 868-8493


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News